Literature DB >> 11247878

Type I collagen degradation does not diminish with RA disease duration.

M Hakala1, K Aho, S Aman, R Luukkainen, M Kauppi, J Risteli.   

Abstract

OBJECTIVE: To assess the relation between type I collagen degradation and the duration of rheumatoid arthritis (RA).
METHODS: The serum concentrations of cross linked carboxyterminal telopeptide of type I collagen (ICTP) measured earlier in a community based series (90 patients) and a hospital based series (59 patients) were re-evaluated with reference to the duration of RA.
RESULTS: The serum ICTP showed a positive correlation with the duration of the disease in the hospital based series (r(s)=0.40, p<0.01) but not in the community based one (r(s)=0.18, p=0.10).
CONCLUSIONS: Type I collagen degradation predominantly reflecting pathological bone destruction does not seem to diminish in longlasting RA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11247878      PMCID: PMC1753623          DOI: 10.1136/ard.60.4.420

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  3 in total

1.  Periprosthetic strain magnitude-dependent upregulation of type I collagen synthesis in human osteoblasts through an ERK1/2 pathway.

Authors:  Junfeng Zhu; Xiaoling Zhang; Chengtao Wang; Xiaochun Peng; Xianlong Zhang
Journal:  Int Orthop       Date:  2009-02-12       Impact factor: 3.075

2.  Different magnitudes of tensile strain induce human osteoblasts differentiation associated with the activation of ERK1/2 phosphorylation.

Authors:  Junfeng Zhu; Xiaoling Zhang; Chengtao Wang; Xiaochun Peng; Xianlong Zhang
Journal:  Int J Mol Sci       Date:  2008-11-26       Impact factor: 6.208

3.  Serological identification of fast progressors of structural damage with rheumatoid arthritis.

Authors:  Anne Sofie Siebuhr; Anne C Bay-Jensen; Diana J Leeming; Adam Plat; Inger Byrjalsen; Claus Christiansen; Désirée van de Heijde; Morten A Karsdal
Journal:  Arthritis Res Ther       Date:  2013-08-14       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.